Skip to main content
. Author manuscript; available in PMC: 2015 May 29.
Published in final edited form as: Hematol Oncol Clin North Am. 2013 Aug;27(4):851–x. doi: 10.1016/j.hoc.2013.01.006

FIGURE 3.

FIGURE 3

Characteristic response pattern with transient lymphocytosis typically peaking within the first 2 months of treatment, followed by gradual resolution over the next 6–8 months. Decrease in lymphadenopathy was consistent from the beginning. Data derived from relapsed/refractory CLL patients treated with single-agent ibrutinib (PCYC-1102 trial) (From data presented at American Society of Hematology Annual Meeting, San Diego, California, December, 2011).